{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T04:04:28Z","timestamp":1750565068126,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 24-year-old man with classical Hodgkin lymphoma was lost to follow-up after metabolic complete remission (mCR). He presented 4 years later with B-symptoms and impaired clinical condition. Relapsed classical Hodgkin lymphoma was diagnosed. PET\/CT revealed stage IVB with liver and spleen involvement. Two liver function\u2013adjusted salvage attempts were ineffective. Pembrolizumab was instituted with gradual clinical improvement. PET was missed before treatment for a life-threatening condition and was performed on day +10 showing a near mCR. A mCR was confirmed before cycle 2, on day +21, underlining\u2014for the first time in the literature\u2014the possibility to achieve very early mCR with pembrolizumab.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005070","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T22:03:16Z","timestamp":1707861796000},"page":"327-329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["How Early Can Checkpoint Inhibitors Induce a Complete Metabolic Response in Chemorefractory Hodgkin Lymphoma?"],"prefix":"10.1097","volume":"49","author":[{"given":"Angeliki N.","family":"Georgopoulou","sequence":"first","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calliope","family":"Zerzi","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaios","family":"Samaras","sequence":"additional","affiliation":[{"name":"Department of Radiology, Laikon General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phivi","family":"Rondogianni","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Evangelismos General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1470-2045(21)00138-8","article-title":"Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3390\/cancers11081071","article-title":"Immunotherapy in Hodgkin lymphoma: present status and future strategies","volume":"11","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib8-20250621","first-page":"204062072090291","article-title":"Optimizing outcomes in relapsed\/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies","volume":"11","year":"2020","journal-title":"Ther Adv Hematol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:45Z","timestamp":1750532805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005070","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}